IL17 and IFN-gamma inhibition for the treatment of autoimmune inflammation

US8592456B2 · kind B2 · utility

Assignee

• 4SC DISCOVERY GMBH · DE

Inventors

• Johann Leban · Planegg, DE
• Stefan Tasler · Hanerau-Hademarschen, DE
• Roland BAUMGARTNER · Birkenfeld, DE
• Wael Saeb · Gräfelfing, DE
• Carine Chevrier · Munich, DE

Key dates

• Filing date: Jan 27, 2012
• Grant date: Nov 26, 2013
• Expiry date: Jan 27, 2032

Classification

• Technology area (CPC A): Human Necessities
• CPC primary: A61P37/08
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

The present invention relates to compounds of the general formula (I), and the pharmaceutically acceptable salt or solvate thereof, as anti-inflammatory and immunomodulatory agents.